NASDAQ:GENE Genetic Technologies (GENE) Stock Forecast, Price & News $0.96 -0.01 (-1.26%) (As of 05:16 PM ET) Add Compare Share Share Today's Range$0.95▼$0.9850-Day Range$0.93▼$1.1952-Week Range$0.83▼$2.40Volume23,849 shsAverage Volume1.41 million shsMarket Capitalization$18.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileChartCompetitorsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media About Genetic Technologies (NASDAQ:GENE) StockGenetic Technologies Ltd. is a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The GeneType/Corporate segment includes tha GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.Read More Receive GENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address GENE Stock News HeadlinesMay 23, 2023 | finance.yahoo.comGeneType featured on U.S. National TV to raise Breast Cancer AwarenessMay 4, 2023 | msn.com'Genetic Havoc' - Five Reasons to Be Concerned About Gene-Edited Teff [analysis]May 31, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>May 2, 2023 | benzinga.comGenetic Technologies Stock (NASDAQ:GENE), Guidance and ForecastMay 1, 2023 | benzinga.comGenetic Technologies Stock (NASDAQ:GENE), DividendsApril 23, 2023 | americanbankingnews.comGenetic Technologies (NASDAQ:GENE) Shares Cross Above 200-Day Moving Average of $1.14March 13, 2023 | finance.yahoo.comBack-to-back Studies Validate geneType Breast Cancer Risk TestMarch 9, 2023 | benzinga.comPreimplantation Genetic Testing Market Value To Top Us$ 1.4 Billion By 2032 : Fact.MR StudyMay 31, 2023 | Behind the Markets (Ad)Small A.I. Firm Wins $2 Billion in Contracts for Breakthrough "Living Software"Denver firm proves its possible to use AI to save the lives of soldiers in combat. England, Germany, Japan and Australia have all signed contracts within the past 18 months. Get the name of the stock here >>>February 27, 2023 | msn.comDecoding genetic technologiesFebruary 7, 2023 | finance.yahoo.comGenetic Technologies Announces Closing of $5 Million Registered Direct OfferingFebruary 6, 2023 | finance.yahoo.comGenetic Technologies to Launch Ground-breaking Comprehensive Risk Test for Breast & Ovarian CancerFebruary 3, 2023 | msn.comWhy Genetic Technologies Shares Are Skyrocketing During Premarket SessionFebruary 3, 2023 | finance.yahoo.comGenetic Technologies Announces $5 Million Registered Direct OfferingFebruary 1, 2023 | marketwatch.comGenetic Technologies Shares Rise 8% After Qiagen PartnershipFebruary 1, 2023 | finance.yahoo.comGTG to form Strategic Alliance with global testing leader QIAGENDecember 8, 2022 | msn.comIndia says GM technology important for food security, import reductionDecember 1, 2022 | finance.yahoo.comSyncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies CorporationNovember 29, 2022 | finance.yahoo.comSyncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies CorporationNovember 15, 2022 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Applied Genetic Technologies CorporationNovember 11, 2022 | wsj.com‘As Gods’ Review: Genetic Technology’s Human RevolutionNovember 10, 2022 | finance.yahoo.comWebinar - Dr Erika Spaeth to interview A/Prof Charles Siles on risk assessment tests for serious diseaseNovember 9, 2022 | finance.yahoo.comGenetype for Ovarian Cancer Published in Prestigious European Journal of Cancer PreventionNovember 8, 2022 | benzinga.comSequencing.com Raises $5 Million In Venture Capital to Fund Groundbreaking DTC DNA TechnologyOctober 27, 2022 | proactiveinvestors.comGenetic Technologies’ breast screening tech 9x more sensitive than current screeningOctober 25, 2022 | benzinga.comGenetic Technologies Announces Q1 FY23 Quarterly Results; Q1 Sales Of A$1.93M An Increase Of 375% From Q1 FY22October 25, 2022 | finance.yahoo.comGenetic Technologies Announces Q1 FY23 Quarterly Results and Investor Webinar DetailsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GENE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genetic Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address GENE Company Calendar Today5/31/2023Fiscal Year End6/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GENE CUSIPN/A CIK1166272 Webwww.gtgcorporate.com Phone(138) 412-7000Fax011-61-3-8412-7040Employees18Year Founded1989Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.03 Current Ratio2.08 Quick Ratio1.98 Sales & Book Value Annual Sales$4.86 million Price / Sales3.79 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.24Miscellaneous Outstanding Shares19,240,000Free Float17,993,000Market Cap$18.42 million OptionableOptionable Beta1.58 Social Links Key ExecutivesSimon MorrissChief Executive OfficerTony di PietroChief Financial Officer & SecretaryRichard AllmanChief Scientific OfficerErika SpaethDirector-Clinical Affairs & Medical EducationCarl StubbingsChief Commercial OfficerKey CompetitorsCyclo TherapeuticsNASDAQ:CYTHSurrozenNASDAQ:SRZNInhibikase TherapeuticsNYSE:IKTSQZ BiotechnologiesNYSE:SQZMicrobot MedicalNASDAQ:MBOTView All CompetitorsInstitutional OwnershipOLD Mission Capital LLCSold 48,631 shares on 5/12/2023Ownership: 0.112%OLD Mission Capital LLCBought 36,742 shares on 3/6/2023Ownership: 0.365%View All Institutional Transactions GENE Stock - Frequently Asked Questions How have GENE shares performed in 2023? Genetic Technologies' stock was trading at $0.93 at the start of the year. Since then, GENE shares have increased by 2.9% and is now trading at $0.9572. View the best growth stocks for 2023 here. What other stocks do shareholders of Genetic Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Genetic Technologies investors own include Vascular Biogenics (VBLT), Caladrius Biosciences (CLBS), Inovio Pharmaceuticals (INO), Novavax (NVAX), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Atossa Therapeutics (ATOS), FuelCell Energy (FCEL) and Heat Biologics (HTBX). What is Genetic Technologies' stock symbol? Genetic Technologies trades on the NASDAQ under the ticker symbol "GENE." Who are Genetic Technologies' major shareholders? Genetic Technologies' stock is owned by many different retail and institutional investors. Top institutional shareholders include OLD Mission Capital LLC (0.11%). How do I buy shares of Genetic Technologies? Shares of GENE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Genetic Technologies' stock price today? One share of GENE stock can currently be purchased for approximately $0.96. How much money does Genetic Technologies make? Genetic Technologies (NASDAQ:GENE) has a market capitalization of $18.42 million and generates $4.86 million in revenue each year. How can I contact Genetic Technologies? Genetic Technologies' mailing address is 60-66 HANOVER STREET, FITZROY C3, 3065. The official website for the company is www.gtgcorporate.com. The biotechnology company can be reached via phone at (138) 412-7000, via email at ir@gtgcorporate.com, or via fax at 011-61-3-8412-7040. This page (NASDAQ:GENE) was last updated on 5/31/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genetic Technologies Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.